All analyses
AI analysis

Laxapana PLC: research report

Moderately undervaluedbearishNov 6, 2026

Evidence points bearish: September-quarter profit fell 46.2% as operating margin contracted. The counterweight is a low P/E relative to manufacturing peers.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bearish

  • September-quarter net profit fell 46.2% year-on-year to LKR 52.7 million as operating margin dropped 5.0 points.
  • Revenue slipped 2.4% while operating profit fell 38.7%, showing that the profit decline came principally from weaker trading profitability.
  • The share rose 5.9% over three months despite the margin contraction, leaving price performance at odds with the latest operations.

Against this. The 9.24 times P/E is below the manufacturing median of 12.78 times and ranks cheaper than 86% of sector peers.

Operating margin
8.5%sector 11.3%
from 13.5% a year earlier
Net margin
5.3%sector 6.6%
from 9.7% a year earlier, revenue -2.4%
Return on equity
18.8%
twelve months to Sep 30, 2026, unaudited
P/E
10.0sector 12.8
earnings Rs 4.29 per share, year to Sep 2026
P/B
1.89sector 1.70
book Rs 22.78 per share
Dividend yield
3.48%sector 1.62%
35.0% of earnings paid out

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Nov 6, 2026. Sector figures are the median of 29 listed companies in the same sector.

Overview

Laxapana manufactures and distributes batteries, LED lighting, pumps, welding rods and steel roofing products through its domestic distribution network. The latest September quarter marked a clear weakening in operating performance after the stronger audited year to March 2026: sales eased and profitability compressed, rather than the improvement continuing into the new financial year.

Price performance

At LKR 44.80 on 5 November 2026, the share had risen 5.9% over three months while the ASPI fell 0.7%; over one year it fell 10.4% against a 6.9% fall in the index. The divergence between the recent share gain and the September margin decline is consistent with the reported tension between price action and operations, but does not establish a cause.

The price sits 28.5% of the way up its 52-week range, or 27.9% below the high. Recent annualised volatility was 43.5%, below its own one-year norm, while 20-day volume was 28.4% above the preceding 60-day pace.

The record since November 2023 is three falls of 15% or more in three years, the deepest 39%, which has not yet recovered. Liquidity is the practical constraint: median daily turnover was LKR 104,624, and a LKR 1 million order is more than everything that trades on a typical day (956% of it).

Valuation

The P/E is 9.24 times, meaning LKR 9.24 is paid for each rupee of trailing profit, versus a manufacturing median of 12.78 times. It ranks at the 14th percentile among sector companies with a P/E, so it is near the cheaper end of that comparison.

The P/B is 1.97 times, or LKR 1.97 for each rupee of net assets, above the sector median of 1.59 times. That premium is less concerning in isolation because audited return on equity was 23.2%, a strong return on the equity base. The company has too little valuation history in the supplied record for a like-for-like comparison with its own past multiples.

The 1.7% dividend yield is below the sector median of 2.9%. Dividends were LKR 1.50 per share in both FY2025 and FY2026; FY2027 presently records only the LKR 0.75 first interim, so it is incomplete rather than evidence of a cut. Across the market, Laxapana scores 54 of 100 on price against book value, earnings and dividends, placing it in the fairly valued band that is the neutral starting point for the stance.

News and sentiment

Direct coverage is thin, with one material article in the last 90 days. It reported the first FY2027 interim dividend of LKR 0.75 per share on 5 November 2026.

The dividend is confirmed to go ex-dividend on 16 November 2026 and is payable on 4 December 2026. Only a buyer before the ex-date receives it; the event transfers cash to shareholders and does not address the weaker September trading result.

Financials

September-quarter revenue fell 2.4% year-on-year to LKR 989 million, while net profit fell 46.2% to LKR 52.7 million. Profit therefore shrank much faster than sales, leaving less profit from each rupee of products sold.

Gross margin was 29.0% versus 29.4% a year earlier, operating margin was 8.5% versus 13.5%, and net margin was 5.3% versus 9.7%. Each margin was among the best two of the three comparable September quarters on group reporting, but the latest result was still below the prior September on each measure. The structural gross-margin pattern does not explain this print: June, not September, has been the strongest quarter on average over the four complete years on record.

Operating profit fell 38.7% to LKR 84.0 million, while LKR 31.3 million of finance costs, tax and other below-operating items separated it from net profit. Equity rose to LKR 1.5 billion and the share count remained 66.2 million, so the earnings deterioration was not caused by a change in ordinary shares. The audited year to March 2026 had delivered 92.1% net-profit growth, but that is an earlier period and the September filing shows the company has since moved into a weaker quarter.

Risks

The principal risk is that the September margin compression persists while sales are also lower. Operating margin lost 5.0 percentage points year-on-year, which matters more than the low P/E if the earnings base has weakened.

Balance-sheet risk has improved but remains relevant. At March 2026, debt was LKR 431.7 million, equal to 31.2% of owners' equity, down from 69.7% a year earlier; operating profit covered the interest bill 7.25 times, up from 4.18 times. The current ratio was 1.54, meaning short-term assets, including inventory and customer receivables, were LKR 1.54 for every rupee of bills due within a year.

Cash conversion was 0.57 times operating profit in FY2026, so not all accounting operating profit arrived as cash. Manufacturing conditions also include higher fuel and input-cost pressure as at 5 November 2026; this is sector context, not evidence of a company-specific impact.

Outlook

As at 6 November 2026, the next company-specific test is the December 2026 interim quarter, expected to be filed between 2 and 14 February 2027. It will show whether the September decline was confined to one quarter or continued into the following period, particularly through gross and operating margins.

The confirmed LKR 0.75 interim dividend goes ex-dividend on 16 November 2026. Beyond that dated cash distribution, the supplied data does not identify a contract, capacity addition or other disclosed event that would independently change Laxapana's earning power.

About this report. Generated on Nov 6, 2026 from market data up to Nov 5, 2026, 1 material news articles over 90 days and financials to Sep 30, 2026, and scored 54 of 100 on value (fairly valued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports